Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
PepLib logo — Rethink Peptide Drug Discovery: Universal-Exact-Diverse

PepLib

Rethink Peptide Drug Discovery: Universal-Exact-Diverse

Founded 2017 China Zhuzhou, China 6 employees Series A Total: $220.00M Biotechnology, Health Care

General Information

Company Name PepLib
Founded Year 2017
Location China Zhuzhou, China +2
Employees 6
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when PepLib moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About PepLib

PepLib is a high-tech biopharmaceutical startup focused on revolutionizing the discovery of new peptide drugs. Established in 2017, PepLib is based in Zhuzhou, China, with a subsidiary in New Jersey, USA. The company's core platform, Peptide Information Compression Technology (PICT), boasts a groundbreaking ZSenithFive® peptide library, containing information on nearly half a billion peptides. In addition to PICT, PepLib has developed 4 complementary peptide discovery platforms, enhancing its capabilities for peptide drug discovery. Securing Series Pre-A financing of 100 million yuan (USD 16 million) in 2019 and Series A financing of 220 million yuan (USD 35 million) in 2021, PepLib is now aiming for Series Pre-IPO financing. With over 190 employees, more than 80% of which are dedicated to research and development, the company is committed to advancing innovation in the treatment of oncology and cardiometabolic diseases. Notably, their oncology programs are focused on the development of peptide drug conjugates (PDCs) and peptide radionuclide conjugates (PRCs). PepLib's recent Series A investment on 30th April 2021 attracted significant funding from investors including Cowin Capital, HighLight Capital, Legend Star, CAS Investment Management, 澳银资本, and Fortune Capital. With a strong financial backing and a focus on critical therapeutic areas, PepLib is poised to make a substantial impact in the biotechnology and healthcare industries.

Taxonomy: Peptide Drug Discovery, Biopharmaceutical, High-tech, Innovation, Peptide Library, Series Financing, Oncology, Cardiometabolic Diseases, R&D, GPCR Targets, Drug Conjugates, Radionuclide Conjugates, High-throughput Screening, Cell-based Assays, Biochemical Assays

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 6
Investor Investor Investor Investor Investor Investor
30 Apr 2021

FAQ About PepLib

Rethink Peptide Drug Discovery: Universal-Exact-Diverse
PepLib was founded in 2017.
PepLib is headquartered in Zhuzhou, China.
PepLib operates in the following industries: Biotechnology, Health Care.
PepLib has approximately 6 employees.
PepLib has completed 1 funding round, raising a total of $220.00M. The latest funding stage is Series A.

We're actively collecting intelligence on PepLib .

Track PepLib to get notified

Don't just browse. Track.

Signal Tracker monitors PepLib and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes